ResearcherInnlandet Hospital TrustActive in the last 2 years
Gabor Istvan Liposits
Matched on ORCID iD 0000-0002-8204-3949; OpenAlex author ID A5032002590. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers
Papers 5
- The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
- NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Last author DOI 10.1016/j.esmoop.2026.108306↗
- A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.1186/s12885-023-11035-6↗
- A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.21203/rs.3.rs-2955930/v1↗
- Conkiss: conformal kidneys sparing 3D noncoplanar radiotherapy treatment for pancreatic cancer as an alternative to IMRT. Co-author DOI 10.1016/j.meddos.2009.11.001↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- T. Kahl · 1 shared paper, 2026 · strength 0.50
- Morten Bækbo Ladekarl · 2 shared papers, 2023 · strength 0.32
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.1186/s12885-023-11035-6↗
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
- Louise S. Rasmussen · 2 shared papers, 2023 · strength 0.32
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.1186/s12885-023-11035-6↗
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
- Britta Weber · 2 shared papers, 2023 · strength 0.32
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.1186/s12885-023-11035-6↗
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
- Stine Brændegaard Winther · 2 shared papers, 2023 · strength 0.32
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.1186/s12885-023-11035-6↗
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
- Julia Sidenius Johansen · 2 shared papers, 2023 · strength 0.32
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.1186/s12885-023-11035-6↗
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
- Per Pfeiffer · 2 shared papers, 2023 · strength 0.32
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.1186/s12885-023-11035-6↗
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
- Inna Markovna Chen · 2 shared papers, 2023 · strength 0.32
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.1186/s12885-023-11035-6↗
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
- Sönke Detlefsen · 2 shared papers, 2023 · strength 0.32
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.1186/s12885-023-11035-6↗
- Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
- Susy Shim · 1 shared paper, 2023 · strength 0.16
- Susy Shim · 1 shared paper, 2023 · strength 0.16
- László Mangel · 1 shared paper, 2011 · strength 0.03
- Zsolt Sebestyén · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.